Company* |
Company* |
Type/Product Area | Terms/Details (Date) |
| |||
Acambis plc (UK; |
Cambridge | Cambridge Biostability |
Acambis retained an option for an exclusive license to market the vaccine, HolaVax-ETEC, in North America; terms of the deal were not disclosed (5/10) |
| |||
Access Pharmaceuticals Inc. (AMEX:AKC) |
Hunter-Fleming | Collaboration for the oral |
They will combine Access's vitamin B-12 oral delivery technology with Hunter-Fleming's Oligotropin (HF0420); terms of the deal were not disclosed (5/12) |
| |||
ActiveSight* |
Lexicon Pharmaceuticals | ActiveSight will perform crystallography services |
The deal extends the co-crystallography of Lexicon's small-molecule compounds to a second drug-target protein validated by Lexicon and expressed by ActiveSight; terms were not disclosed (4/27) |
|
|||
Affitech A/S* |
Undisclosed | The unnamed company gets rights to use the Protein L gene as well as vectors and know-how of Protein L production |
The nonexclusive license covers use with (Norway) research and preclinical development; terms of the deal were not disclosed (5/31) |
|
|||
AlgoNomics |
Genmab A/S | Genmab got rights to access AlgoNomics' Epibase platform for T-cell epitope identification |
Genmab will use the technology in validation of antibody leads; terms of the three- year deal were not disclosed (5/12) |
|
|||
Alnylam Pharmaceuticals Inc. (ALNY) |
Ambion Inc.* | Ambion got rights to provide research products and services under Alnylam's Kreutzer- Limmer patent family |
The patents cover short interfering RNAs and their use to mediate RNAi in mammalian cells; terms of the nonexclusive license were not disclosed (6/8) |
|
|||
Angiotech Pharmaceuticals Inc. (Canada; ANPI) |
Histogenics | Histogenics got rights to use |
Angiotech gets warrants to purchase Histogenics shares, and would share any resulting revenue; it also retains all drug-loaded rights to ChondroGEL (6/2) |
|
|||
Angiotech Pharmaceuticals Inc. (Canada; |
Broncus Technologies | Broncus got rights to use Angiotech's Paclitaxel technology with its Exhale system for treating |
Angiotech gets warrants to purchase Broncus preferred stock, and would get royalties on sales of resulting products (6/2) |
|
|||
Asinex Ltd.* |
Galapagos | Collaboration to optimize leads for Galapagos' validated bone and joint disease drug targets |
Asinex will use its computational chemistry and compound libraries to generate new leads; then they will design and optimize the lead structures; terms were not disclosed (5/12) |
|
|||
Atugen AG* |
Xantos | Atugen will use its siRNA technology to validate a Xantos angiogenic compound in animal studies |
Terms of the deal were not disclosed (4/15)# |
|
|||
BioMarin Pharmaceutical |
Serono SA | Collaboration to further develop and commercialize two BioMarin products, Phenoptin and Phenylase, for treating phenylketonuria and possibly other diseases |
BioMarin gets $25M up front and up to $232M in milestone payments based on the registration of both products in multiple indications, as well as royalties on sales; Serono gets exclusive rights outside the U.S. and Japan (5/16) |
|
|||
BioWa Inc.* |
Medarex Inc. | Medarex got a second license to BioWa's Potelligent technology for enhancing antibody- dependent cellular cytotoxicity |
BioWa gets license fees, and could receive milestone payments and product royalties; Medarex has nonexclusive rights to develop antibodies for an undisclosed number of targets (5/24) |
|
|||
Caliper Life |
Affymetrix Inc. | Affymetrix got nonexclusive rights to use Caliper's microfluidics technology with Gene-Chip microarray technologies |
The deal covers all GeneChip applications; Caliper gets an up-front license fee and (CALP) royalties on future sales covered under the deal (4/25) |
|
|||
Cambridge |
BioInvent International | BioInvent got rights to use CAT's antibody phage-display technology to develop products from its n-CoDeR antibody libraries |
CAT gets an initial license fee and future payments that depend on how many anti- bodies BioInvent and its partners develop using the technology; CAT also is entitled to milestone and royalty payments; as part of the deal BioInvent withdrew its opposition to CAT patents filed in Europe (6/3) |
|
|||
Cellectis SA* |
Celliance (unit of | Celliance will evaluate |
The goal is to develop a new generation of cell lines; terms of the deal were not disclosed (5/31) |
|
|||
Cell Signaling Technology |
Chiron Corp. | CST will perform a pilot project for Chiron using its PhosphoScan technology |
The goal is to identify phosphorylation sites and prospective biomarkers of protein tyrosine kinase targets; terms of the deal were not disclosed (6/1) |
|
|||
Cell Therapeutics |
Cephalon Inc. | Cephalon acquired Trisenox (arsenic trioxide), a product approved for treating acute promyelocytic leukemia |
CTI gets $70M in cash and up to $100M more if certain sales and regulatory milestones are achieved; Cephalon also got rights to a joint proteasome inhibitor research program, and would pay royalties on any resulting sales from that program; Cephalon will offer jobs to CTI commercial employees (6/13) |
|
|||
ChemBridge Research Laboratories Inc.* |
Trimeris Inc. | Collaboration to discover and develop small-molecule HIV entry inhibitors, targeting gp41 and gp120 |
CRL gets funding to support medicinal chemistry efforts, and is eligible to receive milestone payments and sales royalties; Trimeris assumes development and commercial responsibilities (6/13) |
|
|||
Chiron Corp. |
Enanta Pharmaceuticals | Exclusive deal to develop and commercialize Chiron's portfolio of hepatitis C virus protease inhibitors |
Chiron is entitled to milestone and royalty payments, and retains certain co-development and commercialization opt-in rights, excluding Asia; Enanta also got nonexclusive rights to certain HCV technology (5/19) |
|
|||
Crucell NV |
Medarex Inc. |
Program to optimize the application of Crucell's STAR technology in bioreactor |
The program will be performed with a fully human antibody developed using Medarex's UltiMAb technology; terms were not disclosed (6/1) |
|
|||
Cytomyx |
Biomoda Inc.* |
Cytomyx will provide human clinical samples for Biomoda's program to develop diagnostics |
The samples will support validation work on Biomoda's products for detection and targeted treatment of certain cancers; terms of the deal were not disclosed (5/3) |
|
|||
Definiens AG* |
Cenex BioScience |
They formalized an ongoing relationship through the signing of a licensing and co-marketing agreement |
They will work together in the area of high-content screening on a worldwide, non-exclusive basis; terms of the deal were not disclosed (5/9) |
|
|||
Depomed Inc. |
New River |
Deal to use Depomed's oral Gastric Retention delivery technology with New River drug compounds |
New River may acquire rights to use the technology in up to three compounds; Depomed would get an initial payment and potential milestone and royalty payments for each compound advanced (6/6) |
|
|||
Dharmacon Inc. |
Millennium Pharmaceuticals |
Dharmacon will deliver a genome-wide siRNA library covering about 22,000 human genes to Millennium |
The library will enable high-throughput functional genomic studies for target identification and validation; terms of the deal were not disclosed (5/5) |
|
|||
Dimerix |
Starpharma Holdings Ltd. |
They entered a joint venture focused on dendrimer-based GPCR drug discovery and development |
The venture will use Dimerix's Collision technology in the effort; Starpharma formed Dimerix and holds a 30% stake in the start-up company (5/11) |
|
|||
Encysive Pharmaceuticals |
Revotar Bio- pharmaceuticals |
Deal under which Revotar would license bimosiamose and certain follow-on compounds |
The deal is contingent on Revotar's other stockholders investing additional capital in Revotar, which would reduce Encysive's ownership to about 14%; Encysive would get royalties on sales (4/26) |
|
|||
EndoBiologics International Corp.* |
VaxGen Inc. |
Collaboration for research of a vaccine against meningitis serogroup B, using technology developed by EndoBiologics |
VaxGen will fund proof-of-concept studies for a year; if it then exercises its option, VaxGen would provide additional research funding, while EndoBiologics would be entitled to milestone and royalty payments (5/4) |
|
|||
Epigenomics |
Qiagen NV |
Deal to develop a preanalytical solution portfolio for DNA methylation analysis |
The goal of the collaboration is to develop diagnostic kit components; Epigenomics gets up-front technology access and license fees, as well as royalties on all research product sales (5/2) |
|
|||
Europroteome |
Genmab A/S |
Genmab acquired all rights to 16 potential targets to treat non-steroid-dependent cancers of epithelial cell origin |
There are no milestone or royalty obligations in the deal; Europroteome is in insolvency proceedings (5/18) |
|
|||
Exelixis Inc. |
Genentech Inc. (NYSE:DNA) |
Collaboration to discover and develop therapeutics targeting cancer, inflammatory diseases and tissue growth and repair; the work focuses on the Notch pathway |
Exelixis gets up-front and three years of R&D funding totaling $16M; it also is entitled to milestone and royalty payments; Exelixis also has an option to share part of the costs and profits for certain products (6/3) |
|
|||
GeneGo Inc.* |
Exelixis Inc. |
Exelixis licensed GeneGo's MetaCore technology |
The platform is used in drug discovery; terms of the deal were not disclosed (5/13) |
|
|||
Genmab A/S (Denmark; CSE: |
Serono SA |
Serono got worldwide rights to Genmab's HuMax-TAC, a fully human monoclonal antibody being developed for T-cell-mediated diseases |
Genmab gets an up-front payment of $2M and is entitled to milestone payments of up to $38M, as well as royalties on sales from any resulting products; the product is in the preclinical stage (5/2) |
|
|||
Icoria Inc. |
Vesta |
Deal under which Icoria will profile Vesta's adult human liver-derived stem/progenitor cells |
In return, Icoria will gain access to clinical liver samples for use in validating biomarkers and drug targets (4/27) |
|
|||
ImmunoGen |
Genentech Inc. |
They renewed May 2000 agreement giving Genentech certain rights to use ImmunoGen's Tumor- Activated Prodrug technology |
Genentech paid $2M to renew the deal for three years; the original deal was for five years (5/2) |
|
|||
ImmunoGen |
Genentech Inc. |
Genentech licensed rights |
ImmunoGen gets a $1M license payment and is entitled to milestone and royalty payments; the exclusive deal stems from a pact in 2000 giving Genentech rights to test the technology against certain targets (4/28) |
|
|||
Ingenuity |
Serono Genetics Institute (France; unit of Serono SA; NYSE:SRA) |
Serono licensed the Pathways Knowledge Base for use in developing drug discovery and development tools |
Serono also licensed the Pathways Analysis application; terms of the deal were not disclosed (6/14) |
|
|||
InterMune |
Three Rivers Pharmaceuticals |
Three Rivers acquired worldwide ownership of Amphotec/Amphocil (lipid-based amphotericin B) |
The product is indicated for treating invasive aspergillosis; terms of the deal were not disclosed (5/24) |
|
|||
Intradigm |
Acuity Pharmaceuticals |
Acuity got exclusive rights to Intradigm's technology for topical and systemic drug delivery for ophthalmic uses |
They also will collaborate to develop topical formulations of Acuity's Cand5 com- pound; Acuity exclusively licensed rights to Intradigm's siRNA ophthalmic discovery technologies; the deal includes up-front payments and potential milestones and royalties to Intradigm (6/9) |
|
|||
Kalypsys Inc.* |
NovImmune SA* (Switzerland) |
Collaboration to discover |
They will pair Kalypsys' screening technology, chemical library and small-molecule capabilities with NovImmune's expertise in immunoregulation and MHC Class II-associated biology; terms were not disclosed (6/16) |
|
|||
Luminex Corp. |
Digene Corp. |
Digene gained access to Luminex's xMAP bead-based multiplexing technology for use in women's health diagnostics |
Digene intends to commercialize in vitro clinical diagnostic tests under the non-exclusive license; terms of the deal were not disclosed (5/5) |
|
|||
Medicago |
InterveXion Therapeutics |
Deal to use Medicago's |
Medicago would get milestone payments to produce the phencyclidine (PCP) antibody; an expanded deal to include another antibody is expected (6/6) |
|
|||
Mera Pharmaceuticals Inc. (OTC |
Rincon Pharmaceuticals |
Collaboration to demonstrate the scalability and economics of using microalgae as a protein expression system |
Mera will use its technology to perform pilot studies on up to six antibodies; Rincon has an option to use the technology to develop its own production capability; terms were not disclosed (5/12) |
|
|||
Myriad Genetics |
Salmedix Inc.* |
Salmedix got exclusive rights to use the single R-enantiomer of etodolac |
The license provides additional protection to Salmedix for its cancer candidate SDX-101; Myriad gets $2.5M up front and is entitled to milestone and royalty payments (5/24) |
|
|||
NanoCarrier |
Debiopharm SA* (Switzerland) |
Debiopharm got an option to license a DACH Platin Medicelle platinum-based compound for oncology applications |
Debiopharm will fund product development; NanoCarrier is entitled to receive milestone payments and royalties on any sales (4/21) |
|
|||
NovImmune SA* (Switzerland) |
Serono SA (Switzerland; NYSE:SRA) |
Serono got worldwide rights to two fully human monoclonal antibodies, NI-0401 and NI-0501, which may have potential in autoimmune diseases |
NovImmune gets a $5M license fee, a $6M equity investment, and a convertible loan of up to $6M; it also could get up to $105M in milestone payments, as well as royalties on sales (5/17) |
|
|||
Nuevolution |
Biovitrum |
Nuevolution will use its Chemetics technology to discover new drug leads against a Biovitrum target |
Nuevolution is entitled to certain milestone payments and a share of any future product sales (6/13) |
|
|||
OncoMethylome Sciences SA* (Belgium) |
Exact Sciences |
Deal to evaluate certain gene methylation markers for use with Exact's colon cancer screening technology |
The markers were identified at Johns Hopkins University and are exclusively licensed to OncoMethylome; terms of the deal were not disclosed (6/7) |
|
|||
OriGene Technologies |
Regeneron Pharmaceuticals |
Regeneron got a license to OriGene's TrueClone collection of full-length human cDNAs |
Regeneron will use the technology in its protein expression and target validation platforms; terms were not disclosed (4/27) |
|
|||
Penwest Pharmaceuticals |
Prism Pharmaceuticals |
Prism got exclusive rights to market Penwest's beta-blocker PW2101 in the U.S. and Canada |
The product is under review by the FDA for treating hypertension and angina; Penwest got $4M up front and could get $9.5M in milestones if the product is approved by Dec. 31, 2005; Penwest would get royalties of 15% to 18% (4/27) |
|
|||
Seattle Genetics |
MedImmune |
MedImmune got rights to use antibody-drug conjugate technology with antibodies against a single tumor target |
Seattle Genetics gets $2M up front and annual maintenance fees, and is entitled to milestone and royalty payments; Med- Immune also has an option to access the technology for a second antibody program for an additional fee (4/28) |
|
|||
To-BBB BV* |
Genmab A/S |
Genmab will evaluate To-BBB's technology for delivering antibodies across the blood-brain barrier |
Genmab has an option to license the technology for use with two antibodies; To-BBB is eligible to receive milestone and royalty payments (5/24) |
|
|||
TranXenoGen |
A.C.T. Holdings |
A.C.T. and subsidiary Advanced Cell Technology Inc. got an option for exclusive rights to cloning patents |
Separately, A.C.T. acquired rights to a cloning technology known as "cell fusion" and patents related to gene trap technology; terms of the deal were not disclosed (5/19) |
|
|||
Vical Inc. |
AnGes MG |
AnGes gained exclusive rights to use Vical's nonviral gene delivery technology for cardiovascular applications |
The license covers DNA-based products encoding hepatocyte growth factor; Vical gets $1M up front, and is eligible for milestone and royalty payments (5/24) |
| |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
# Item occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; SSE = Stockholm Stock Exchange. |